The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism

I. Kivilcim Oguzulgen, Senay Demirtas, Ferda Oner Erkekol, Numan Ekim, Nalan Demir, Numan Numanoglu, Duygu Ozel, Arzu Ulu, Nejat Akar

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0% and 7.7% of the cases and controls, respectively, P =.001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.

Original languageEnglish (US)
Pages (from-to)73-77
Number of pages5
JournalClinical and Applied Thrombosis/Hemostasis
Volume15
Issue number1
DOIs
StatePublished - Feb 2009
Externally publishedYes

Fingerprint

Plasminogen Activator Inhibitor 1
Prothrombin
Pulmonary Embolism
Mutation
Genes
Alleles
Venous Thromboembolism
factor V Leiden
Genotype
Recurrence

Keywords

  • Factor-V-Leiden
  • Genetics
  • Plasminogen activator inhibitor-1
  • Prothrombin-20210
  • Pulmonary thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. / Oguzulgen, I. Kivilcim; Demirtas, Senay; Erkekol, Ferda Oner; Ekim, Numan; Demir, Nalan; Numanoglu, Numan; Ozel, Duygu; Ulu, Arzu; Akar, Nejat.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 1, 02.2009, p. 73-77.

Research output: Contribution to journalArticle

Oguzulgen, I. Kivilcim ; Demirtas, Senay ; Erkekol, Ferda Oner ; Ekim, Numan ; Demir, Nalan ; Numanoglu, Numan ; Ozel, Duygu ; Ulu, Arzu ; Akar, Nejat. / The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. In: Clinical and Applied Thrombosis/Hemostasis. 2009 ; Vol. 15, No. 1. pp. 73-77.
@article{e9a75dee93fa4dabab01158fd53199f8,
title = "The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism",
abstract = "Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0{\%} and 7.7{\%} of the cases and controls, respectively, P =.001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.",
keywords = "Factor-V-Leiden, Genetics, Plasminogen activator inhibitor-1, Prothrombin-20210, Pulmonary thromboembolism",
author = "Oguzulgen, {I. Kivilcim} and Senay Demirtas and Erkekol, {Ferda Oner} and Numan Ekim and Nalan Demir and Numan Numanoglu and Duygu Ozel and Arzu Ulu and Nejat Akar",
year = "2009",
month = "2",
doi = "10.1177/1076029607305110",
language = "English (US)",
volume = "15",
pages = "73--77",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - The role of plasminogen activator inhibitor-1 polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism

AU - Oguzulgen, I. Kivilcim

AU - Demirtas, Senay

AU - Erkekol, Ferda Oner

AU - Ekim, Numan

AU - Demir, Nalan

AU - Numanoglu, Numan

AU - Ozel, Duygu

AU - Ulu, Arzu

AU - Akar, Nejat

PY - 2009/2

Y1 - 2009/2

N2 - Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0% and 7.7% of the cases and controls, respectively, P =.001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.

AB - Polymorphism in plasminogen activator inhibitor-1 gene is suggested to be associated with an increased risk of venous thromboembolism. The aim of this study was to investigate the association of plasminogen activator inhibitor-1 gene polymorphism and its coexistence with factor-V-Leiden and prothrombin-20210 mutations in pulmonary thromboembolism. The authors investigated plasminogen activator inhibitor-1 4G/5G polymorphism, factor-V-Leiden, and prothrombin-20210 mutations in 143 pulmonary thromboembolism patients and 181 controls. Plasminogen activator inhibitor-1 4G/4G, 4G/5G, and 5G/5G gene polymorphisms and prothrombin-20210 mutations were not different between cases and controls. Factor-V-Leiden mutation was present in 21.0% and 7.7% of the cases and controls, respectively, P =.001. Neither different plasminogen activator inhibitor-1 genotypes and 4G allele nor coexistence of the allele with factor-V-Leiden or prothrombin-20210 was associated with the risk of recurrence. As a result, plasminogen activator inhibitor-1 gene polymorphism or its concomitant presence with mentioned mutations was not found to be associated with increased risk for pulmonary thromboembolism or recurrent disease in this study.

KW - Factor-V-Leiden

KW - Genetics

KW - Plasminogen activator inhibitor-1

KW - Prothrombin-20210

KW - Pulmonary thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=58449097602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58449097602&partnerID=8YFLogxK

U2 - 10.1177/1076029607305110

DO - 10.1177/1076029607305110

M3 - Article

VL - 15

SP - 73

EP - 77

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 1

ER -